Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree with Meach2... the FDA is asking for additional data, not asking for a new study...
I think we are all reading too much into this... This is the FDA... this is the Government... things take time... I still believe Porky's timeline, I think we get approval to start trials in October....
I believe we get a new IND application for MIN Technology within 3-4 weeks...
Hold tight, people... we are all going to be winners from BMSN... both financially and medically.
Question....
I do not understand.... Is a Company (such as TADF) required to put out any financials? Are the REQUIRED to put out the 10K? If so, and they don't do it in a reasonable timeframe, doesn't the Company get in big trouble for that? I am a bit confused as to TADF not putting out any financials and not having to answer for it??
Am I totally missing the boat?
(As my name suggests, I've only been in pinky land about a year and am constantly learning something new each day... any and all help is appreciated)
TIA
-Michele
Received at 7:05pm EST Tuesday
BMSN is my must see new pick!
This subpenny could hit a penny Wednesday!
Hello Traders!
A lot of biotech plays are really lightweights dressed up in heavyweight clothing – just imagine Manny Pacquiáo trying to pass himself off as Mike Tyson.
BMSN on the other hand is different, night and day different.
Last time I introduced a company like this it soared triple digits. I have the same confidence here when it comes to BMSN. Don't be surprised if BMSN blows through a penny Wednesday, which would represent a gain of 233%.
Introducing BMSN which closed Tuesday at .003
This biotech dynamo is a massive player in the research and development of cutting edge drugs and therapies and has a strong presence in the $32 billion a year stem cell research industry.
As a result of this very broad and potent profile, BMSN attracts very strong investor attention. Average volume in BMSN is a staggering 27 million+ shares and so when the gain potential presents itself, it is absolutely huge.
How huge?
Right now based on the massively undervalued valuation of BMSN, investors can lock up gain potential of more than 450%.
Wall Street has been taking note too and since December last year more than 1400% has been added to lower valuations.
In other words, BMSN is on the move and all the indicators suggest that the pace will get a shot of adrenaline soon.
Biotech opportunities as real as BMSN don’t come along often so don’t hesitate to make a move on this one.
The sooner you complete your research the quicker you can get in on the action.
Investor Highlights
BMSN has added more than 1400% to its 52-week low of 0.0002 since December last year.
BMSN has a RSI of 45 and is trading on a solid volume growth curve.
BMSN has seen strong movement in several of its key moving averages, including its 200-day MA which is up 383%
BMSN has entered into a license agreement for the development of vaccines using ddRNAi gene silencing technology. This is expected to increase the company’s growth potential in the near and medium terms.
BMSN now has strong strategic footing in the RNAi industry courtesy of its appointment of Dr. David Suhy, a pioneer in the field of RNA Interference (RNAi). Dr Suhy will lend his expertise as a member of BMSN’s strategic advisory board.
BMSN is well placed in the stem cell products industry which was worth more than $4.6 billion in 2012.
BMSN through its subsidiary Regen BioPharma, is busy wrapping up patent applications in support of its Investigational New Drug (IND) application (#15376) with the U. S. Food and Drug Administration (FDA).
BMSN is a massive player the development of cancer gene silencing technology, a presence which exposes the company to and industry with more than $70 billion a year in revenues.
About BMSN
BMSN (Bio-Matrix Scientific Group Inc.) is a biotechnology research and development company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.
BMSN is pursuing relationships with hospitals, medical institutes, research firms and biotechnology companies to assist in stem cell research, cell culturing and Regenerative Medicine therapies.
BMSN’s facilities are available for processing, culturing and storage of specimens. Also, under certain situations, the Company has laboratories available to organizations conducting research.
BMSN to Benefit from Strong Stem Cell Market Outlook
A new report by Visiongain predicts that the overall world market for stem cell technologies in medicine will reach $7.3 billion for 2014. That market will be stimulated by new treatments and increasing use of related products in drug development. Those findings appear in Stem Cell Technologies: World Market Outlook 2012-2022, published in May 2012. Visiongain is a business information provider based in London, UK.
Visiongain forecasts that the stem cells market will expand rapidly from 2012 to 2022, achieving multi-billion-dollar revenues worldwide. More than 200 companies operate in that field. The next ten years will result in many new medical products and uses for stem cells. The period to 2022 will establish the foundations of a therapeutic revolution, the report concludes.
Haematopoietic stem cell transplantation is an established treatment for blood cancers. Revenues from transplants of bone marrow, peripheral blood and umbilical cord blood form much of the market in 2012.
Banking of umbilical cord blood (other stem cell-containing blood units) and culturing and processing of stem cells for laboratory work are the other established business areas in 2012. That commercial activity is only the start, the report argues, with stem cell technologies poised for important advances by 2020.
Dr James Evans, a pharmaceutical industry analyst in visiongain, explains: “Stem cell technologies have been hyped for a long time, but it’s only now that we’re going to see the first approved products, treatments based on mesenchymal stem cells or improvements to stem cell transplants.
Stem cell-based innovations are likely in the treatment of vascular diseases, autoimmune diseases, diabetes, dry AMD and other serious disorders. Some of these breakthroughs will be a commercial reality by 2022.
“The use of stem cells in laboratory assays for drug development is a strong opportunity for the biotechnology industry.
Stem cells offer an improved way to model diseases in vitro, identify candidate drugs and perform toxicity testing and other assays. With drug development costs and failures such a concern for the pharmaceutical industry, that segment will be important to the overall stem cells market, representing around a third of its revenues by 2022, our study predicts.”
With BMSN pioneering so many offerings in the stem cell space, its growth potential should benefit immensely from these robust projections. $7.3 billion is an absolutely huge market from which to tap profits and I expect BMSN to do no less.
Recent Developments
Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board
SAN DIEGO, CA--(Marketwired - Sep 17, 2013) - Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced that it has recruited, Dr. David Suhy, a pioneer in the field of RNA Interference (RNAi), to join the Scientific Advisory Board of Regen BioPharma Inc. ("Regen"), a subsidiary of Bio-Matrix Scientific Group Inc.
"Dr. Suhy, a pioneer of the RNAi industry, was already developing therapeutic candidates in this field in 2003 before the concept of RNAi was accepted in the scientific community," said David Koos, Chairman & CEO of Regen. "We are excited to apply Dr. Suhy's experience in the development of our RNAi based cancer therapeutic."
Regen's Chief Scientific Officer, Dr. Thomas Ichim, noted, "Dr. David Suhy, senior vice president of research and development at Tacere Therapeutics (a subsidiary of Benitec Biopharma), leads all Tacere's clinical development programs.
He was one of the inventors of TT-034, a novel therapeutic product containing three separate RNAi elements targeted against the Hepatitis C virus, and has directed development of the TT-03x series of compounds which target the Hepatitis C virus (HCV), from the drawing board through to Investigational New Drug (IND) enabling studies."
A spokesperson for the Company provided further insight on RNAi, stating this is a process by which genes may be selectively blocked using a natural mechanism the body normally uses to protect against viruses.
The Nobel Prize in Medicine was awarded to Fire and Mello in 2006 for making this discovery. Benitec has been granted international patents on RNAi which have been licensed to Regen for one specific gene, indolamine 2,3 deoxygenase (IDO), which is associated with cancer's ability to suppress the immune system.
Regen Chief Scientific Officer Dr. Thomas Ichim together with Professor Weiping Min at the University of Western Ontario has successfully treated breast cancer (1) and melanoma (2) in animals using this approach.
"With Regen's background in the field of tumor immunology, their licensed intellectual property from Benitec Biopharma, and clinical expertise, I look forward to assisting the Company in developing their protocols with the end goal being taking this safe and nontoxic cancer therapy to patients," said Dr. Suhy.
BMSN is clearly on the front lines of the fight against cancer and so its gain potential shouldn’t be taken lightly. As I mentioned above, the big push to its 12-month high could yield gain potential of more than 450%. I really like this play.
Start your research right now.
Warm Regards,
Alexander Reeves
info@pennypicks.net
Here is the good news... (the bolded portion)... this tells me the animal studies in mice have already been done and the FDA has more questions... understandable in a NEW treatment...
I do not feel this will be 6-12 months... I beleive 2-3... I think it was Porky who said December is the timeline for the actual approval to start the human trials... I believe he is correct.
Subsequently the FDA responded with a second series of comments relating to cellular responses in mouse models of aplastic anemia. Regen BioPharma has been in discussions with Dr. Wei-Ping Min, who also sits on the company's scientific advisory board regarding responding to the FDA comments. On September 24th, Dr. Min signed a services agreement for conducting the animal studies requested by the FDA.
I just posted a note over there on the other board for them... not sure if anyone will see it as it looks like there has been no postings for months....
I believe this was posted on the wrong board and should be listed here...
9/23, 9.24, 9/25
check the filings regarding JC Morgan
http://ih.advfn.com/p.php?pid=squote&symbol=essi
sterv...
THANKS for the update... great DD...
So it appears it is in error and the filing has nothing to do with us... If that is the case, I wonder if the "real" eaton shareholders are aware!!
I really like this part: Another IND application!
Regen identified the following milestones in the anticipated further development of dCellVax:
a) Generation of human dCellVax: 2 months
b) In vitro demonstration of dCellVax efficacy: 1 month
c) FDA-requested toxicology: 4 months
d) IND submission: 1 month
.0005
Court on Monday....
put mine out there at 0.01!
Nice jump in pps... let's see once the news gets out what will happen....
Can you post a link? Where did you hear this?
Rocco-
I have to admit... I do not understand this... Can you help me?
Here are some of the key items that I think are good...
The Company has recently finished its first Clinical Trial Protocol, and is prepared to conduct the Study. On May 14, 2013, the Company entered into a Clinical Trial/Study Agreement with the American Institute of Research (the “CTS Agreement”) to, among other things, conduct the Study. The purpose of the Study will be to demonstrate that Tropine 3, its novel new indication of Homatropine, and existing FDA Approved drug currently used to treat heavy coughing, has the ability to provide relief to pre-menopausal, menopausal and post-menopausal women suffering from hot flashes. The Company’s technical mission is to prove its central thesis that Homatropine in an oral suspension formula can reduce hot flashes in pre-menopausal, menopausal and post-menopausal women through multiple clinical trial validations
On May 14, 2013, the Company entered into a Clinical Trial/Study Agreement with the American Institute of Research (the “CTS Agreement”). The purpose of the Study will be to demonstrate that Tropine 3, its novel new indication of Homatropine, and existing FDA Approved drug currently used to treat heavy coughing, has the ability to provide relief to pre-menopausal, menopausal and post-menopausal women suffering from hot flashes. Pursuant to the CTS Agreement, the cost for the Study is approximately $257,875, based upon 50 (fifty) patients, not to exceed a cost of $5,037.50 per patient, plus preparation and pharmaceutical fees of $6,000.
On September 1, 2012, the Company entered into an employment agreement with Mr. Michael J. Borkowski (the “Employment Agreement”) to serve as the Company’s President, CEO, and Director of the Board of Directors. The Employment Agreement is for a term of three years, and includes compensation in the amount of $72,000 per year, bonus compensation in the amount of $100,000 contingent upon the Company meeting certain goals, 5,000,000 stock options, and certain other benefits in the event they are offered by the Company in the future. As of July 31, 2013 and January 31, 2013, respectively, $38,000 and $6,000 has been recorded as related party unpaid compensation.
In July 2012, the Company effected a 4-to-1 reverse split, whereby each shareholder would receive one (1) share of common stock for each four (4) shares of common stock held. The reverse split resulted in the 100,000,000 shares issued and outstanding to be reduced by 75,000,000 shares, leaving 25,000,000 total shares of common stock issued and outstanding.
GREAT DD, Moon....
Paletta-
It does not take decades to get the initial approval from the FDA to start the trials... this is the stage we are in and waiting for.
Foxwater... I don't have Private Messaging... can you give me your email?
I don't understand something... I thought Pleasant Kids was part of EXPU... a division, if you will... Even though EXPU stopped "production" of plastic bottles, how is it that Pleasant Kids can be acquired by and now be part of NY Bagel Deli? And I am under the impression the NY Bagel Deli is carrying L'Apina?
Or am I completely missing something here?
yes, I agree... but can I watch it online? DO you know the link to see it live?
Can we watch Adrianna on-line today? Maybe she'll mention L'Apina?
Wow... I am confused (again)... I am not sure what RR has to do with anything... Can someone explain what his legal issues are and how they effect us? Is the tweet about the lawyer due to the awful things being said about the Adriana?
My apologies, but I am really lost...
Thanks, Michele
Question...
What do we think will happen if the next PR we get is about the IND application for MIN technology(BEFORE we can the approval to start trials for Hema)...
How do we see this playing out as far as the pps goes? Because I see this as a real possibility
Thank you... I would think this has to do with TADF...
http://www.flightglobal.com/news/articles/usa-and-indonesia-formalise-ah-64e-apache-deal-389856/
The USA will sell Indonesia eight Boeing AH-64E Apache Longbow helicopters in a deal worth $500 million.
The deal was announced at a joint press conference in Jakarta between US defence secretary Chuck Hagel and Indonesian defence minister Purnomo Yusgiantoro, according to a US Department of Defense statement.
"Providing Indonesia these world-class helicopters is an example of our commitment to help build Indonesia's military capability," said Hagel.
He said the helicopters will assist in dealing with "a range of contingencies, including counterpiracy operations and maritime awareness".
As part of the deal, Indonesian pilots and support crews will receive training from the US military. Details of delivery and training are still being ironed out.
In September 2012, the US Defense Security Cooperation Agency (DSCA) notified congress that Jakarta was seeking eight Apaches in the US Army's new Block III configuration, with the Foreign Military Sales (FMS) deal to include four APG-78 Longbow fire control radars. The sale would also cover the supply of further equipment and services, including an armaments package to include 120 Lockheed Martin AGM-114 Hellfire air-to-surface missiles.
At the time, the DSCA valued the deal at $1.4 billion. Given FMS conventions, this value likely included elements such as weapons and long-term, complete lifecycle support for the helicopters.
In recent years, Jakarta has greatly enhanced its ground attack capabilities. When the Apaches arrive, they will complement the 16 Embraer EMB-314 Super Tucano light attack aircraft that Indonesia is in the process of introducing to its air force.
Indonesia has suffered periodic insurgencies in provinces such as Aceh and West Papua, creating a niche for counter-insurgency aircraft in the nation's air force.
Moom- Do you have a ny links where I can read about this? This is the first (I think) I hearing of it...
TIA -Michele
Thanks, FlaFlyersFan....
I am curious... there are several "pumpers" on that list that say they have been oompensated up to $15,000... is that a scripted answer?
http://ija.org/IJAOfficers/Novak.htm
Judge Rita Novak has been as an associate judge of the Circuit Court of Cook County since 1999. Following assignments in child protection, domestic violence, and traffic court, she now serves in the Law Division, Tax and Miscellaneous Remedies Section.
Most of Judge Novak’s pre-judicial career was spent in public service. She was chief of the civil appeals division of the Illinois Attorney General’s Office, an assistant professor of law at Indiana University at Indianapolis, and an assistant project director at the American Bar Association. Her practice focused on constitutional, regulatory, and employment law. She litigated cases in both federal and state courts of review. At the American Bar Association, she worked with state appellate courts throughout the county to assist them in reducing delay and co-authored a book, “Delay on Appeal: A Process for Identifying Causes and Cures.” Judge Novak is a graduate of DePaul College of Law and received an LL.M. from Columbia University School of Law.
Before starting on a career in the law, Judge Novak entered the Peace Corps, where she worked with groups of rural women in Colombia, South America. She maintains an abiding interest in Hispanic language and culture, as evidence by serving as a member of the leadership council of the Midwest Immigrant and Human Rights Center and as a tutor in an after-school program at Casa Central, in Chicago’s Humboldt Park neighborhood. An active participant in professional associations, Judge Novak coordinated a mentor program for the IJA, which paired judges with high school students from disadvantaged areas to enrich their learning experiences. She has held positions on the Illinois State Bar Association special committee on ethics, the access to justice advisory board, and section councils. She served on the boards of directors and other committees of the Women’s Bar Association and the Appellate Lawyers’ Association. The Supreme Court appointed her to the executive committee of the Illinois Judicial Conference and to the Character and Fitness Committee. Judge Novak is a frequent faculty member for continuing judicial and legal education programs. She has also been an adjunct faculty member at Loyola University School of Law and IIT Chicago-Kent College of Law.
A life-long city dweller, Judge Novak lives in Chicago’s South Loop. She enjoys attending cultural events, foreign travel, and studying Spanish and Italian.
Activity Date: 9/18/2013 Participant: PLAY BEVERAGES LLC
PROTECTIVE ORDER - ALLOWED -
Judge: NOVAK RITA M.
According to this site, Stock Braniac was NOT compensated....
http://stockpromoters.com/View-Stock-Promotions-By-Symbol.aspx?symbol=axlx&ctl00%24ContentPlaceHolderyy%24Footer1%24Image2.x=13&ctl00%24ContentPlaceHolderyy%24Footer1%24Image2.y=11
Promoter: The Stock Brainiac
Compensation: None Listed or Image Compensation, Please Read View Message View Message Post to Twitter Post to Facebook
Date: 9/18/2013 - See more at: http://stockpromoters.com/View-Stock-Promotions-By-Symbol.aspx?symbol=axlx&ctl00%24ContentPlaceHolderyy%24Footer1%24Image2.x=13&ctl00%24ContentPlaceHolderyy%24Footer1%24Image2.y=11#sthash.QFASAsCa.dpuf
Not sure how reliable this site is... I can only find 1 promoter currently pumping AXLX that is being compensated, and being compensated by a third party...
Can anyone else confirm or deny?
http://stockpromoters.com/View-Stock-Promotions-By-Symbol.aspx?symbol=axlx&ctl00%24ContentPlaceHolderyy%24Footer1%24Image2.x=13&ctl00%24ContentPlaceHolderyy%24Footer1%24Image2.y=11
Promoter: Wall Street Live Chat
Compensation: - Wallstreetlivechat.com was compensated $1,000 starting on 09/16/13 from sctockchat.de as a marketing budget for 1 day to manage a comprehensive investor awareness program including the creation and distribution of this report as well as other investor relations efforts. View Message View Message Post to Twitter Post to Facebook
Date: 9/16/2013 - See more at: http://stockpromoters.com/View-Stock-Promotions-By-Symbol.aspx?symbol=axlx&ctl00%24ContentPlaceHolderyy%24Footer1%24Image2.x=13&ctl00%24ContentPlaceHolderyy%24Footer1%24Image2.y=11#sthash.QFASAsCa.dpuf
Received email alert at 11:21am EST from JetLife info@jetlifepennystocks.com
---=AXLX: Breaking News=---
Axiologix Signs $5 Million Revolving Credit Facility
With TCA Global Credit Master Fund To Support Growth And Advance Acquisition Efforts!
Sept. 19, 2013 Axiologix, Inc. (www.axiologix.net) (AXLX), an International Technology and Services Organization focused on delivering 'Cloud' Products and Services, today announced that on September 12, 2013, it and all of its wholly owned subsidiaries closed a Senior Secured Revolving Credit Facility of up to $5 million with TCA Global Credit Master Fund, LP ("TCA") to provide operating capital and fund acquisitions.
An initial draw of 250,000usd, less transaction expenses and necessary debt reduction payments, netted 157,000usd for use in existing operations. The Company intends to use the remaining facility primarily to fund revenue and profit accretive acquisitions.
Additional draws under the facility are available on an as-needed basis, based on a mutually approved formula of eligible receivables and assets, subject to continuing compliance with the terms of the revolving credit facility.
Also, as a condition of the facility, the Company agreed to register its shares of common stock with the Securities and Exchange Commission (SEC), through the filing of a SEC Form 10, within three months of the Closing.
For additional information on this financing and related transactions and exhibits please refer to the Company's filings with the OTC Markets Disclosure Service at http://www.otcmarkets.com/stock/AXLX/filings
Vincent Browne, Chairman and Chief Executive of Axiologix, Inc. said,
"This is another significant event in our development and growth plans. This facility with TCA forms a key pillar in our funding capability and, with another strong funding partner behind us, demonstrates to customers, partners and targeted acquisitions collectively that we are in a position to execute.
Whereas, this facility may not be suitable for all acquisitions, the confidence that such proof of funds provides and our ability to move quickly on transactions should make us more attractive to potential sellers and provide an advantage in competitive negotiations.
We look forward to building a strong relationship with TCA over the coming months and years."
Corporate Press Release e-Mail Distribution - Interested investors and shareholders will be added to the corporate e-mail database for future corporate press releases and industry updates after sending an e-mail with "AXLX" in the text to investorrelations@mindspring.com.
About TCA Global Credit Master Fund, LP
TCA Global Credit Master Fund, TCA, is a short duration, absolute return fund specializing in senior secured lending and advisory services to small, mainly listed companies predominately in the U.S., Canada, Western Europe and Australia.
TCA's specialist business fills the underserved small-cap lending gap that exists in these leading markets. The TCA team has an unparalleled level of domestic and cross-border expertise, long-standing relationships and a history of comprehensive funding innovations.
This reflects in its history of successful, completed transactions and high level of repeat business. Additional information may be found at www.tcaglobalfund.com
http://finance.yahoo.com/news/axiologix-signs-5-million-revolving-142100055.html
Axiologix, Inc. | Ticker: AXLX
http://www.axiologix.net/
Float: 359.6m
---=Crew!...
AXLX is a fast flying stock with a very low float that currently trades at only .0005 and has a $3m merger on the table right now that the market is Going crazy Over!
Volume precedes and We all know how fast these triple zero stocks can move once that volume starts flying in..
Take a look..
AXLX Cleared for Technical Take OFF?
AXLX Smashed through ALL short term averages on very nice Volume over the last few days!
AXLX RSI is just a few trades away from that power zone which should push this fast flying stock past that 200 day moving average @ .0007+ no problem = Easy 40+pct
AXLX MACD is not only positive, but its starting to open up with plenty of room up to the next level of volume resistance!
Daily CMF = BULLISH!
AXLX looks powerful for fast short term profits on a quick trade starting tomorrow..
And even better on the weekly!
AXLX - So obvious its NOT Scary?
It is if you see what we see.. And yes.. ITS OBVIOUS!
The last time the AXLX moving averages were this bullish the stock blasted off all the way to the Bank!
Take another look..
AXLX traders who took positions at these levels the last time watched this stock run for weeks = 1300+pct
And that`s on the low end.. The Very Low End!
Much more was made if you traded this this low floater all the way to the Top! YOU think those traders are gone?..
Think Again!
AXLX traders are grabbing whatever shares they can at these levels, licking their percentage chops looking for another move back up to & PAST that 52-week High of .0029
Analyze the AXLX opportunity but don`t hesitate!
Get started on your research, Decide on a trading strategy NOW and take action as soon as you’re confident.
AXLX is creating a nationwide Service Provider of Voice, Data and Cloud services to small and medium size businesses primarily in the United States, and to other operators globally, by acquiring strategic technology assets and existing turnkey VoIP and independent operators.
AXLX`s clear strategy is to make carefully selected acquisitions that will improve shareholder value by using group resources to ensure each operating company have the tools they need to be competitive in the market place and benefit from the economies of scale provided by a larger organization that are not available to them on their own.
AXLX Growth Strategy
This opportunity has arisen from the large number of new entrants into the emerging VoIP Telecommunications market over the past number of years that have been successful in acquiring customers and revenues but are unable to achieve sufficient scale to deliver sustainable growth without further investment that has been hard to find in recent years.
AXLX focuses on acquiring companies that have proven existing revenue streams with neutral or positive cash-flows/EBITDA at time of acquisition so that greater profits can be generated from the combined entities.
AXLX Benefits
Axiologix's operating companies benefit from the economies of scale associated with becoming part of a larger group; they are more competitive, have greater resources to draw from and are more secure financially.
All of which offers security to their business and their customers and facilitates further organic growth.
In the last fiscal year ended May 31, 2013 (just announced on Monday), AXLX showed growth in revenue of over 480% versus the previous year.
http://finance.yahoo.com/news/axiologix-inc-files-annual-report-180200269.html
With gross margins of 95%, the company has already announced a proposed merger with Velocity Networks, Inc. which, if completed, would add 5 Million in revenues and generate annual net income of 1 million.
http://finance.yahoo.com/news/axiologix-inc-attain-profitability-velocity-141500640.html
AXLX also announced a LOI with an undisclosed company with annual revenues of over 3 Million dollars and EBITDA of 300,000 - 450,000usd which operates its own network, delivering Wireless/Wimax, Metro Ethernet and Fiber based services.
Its hosting platforms provides VoIP, Hosted PBX, DNS, E-mail Services; Web & Database Management; Data Center Collocation; VPN & Secured Network Services and Monthly Maintenance services to a client base of over 600 businesses.
http://finance.yahoo.com/news/axiologix-continues-acquisition-plans-addition-125000109.html
Should both these mergers close, AXLX will go from almost a 1 Million revenue company to over 9 Million in annual revenue and a profitability of over 1.3 Million.
Learn more about the people profits and potential
by visiting the AXLX website.
Axiologix, Inc. | Ticker: AXLX
http://www.axiologix.net/
I have 1 million (it's all I could afford to lose!)
Wow... some small fries (like me with 1.2 million) and some big guns with over 100 million.... Let's just hope that when (or IF) news hits, people make their profits and sell wisely!
Here's hoping we all make some money!
$TADF!
I'm only holding 50,000 shares... sold the rest for breakeven... these are "freebies"
ok, up 22%.... volume surpasses our average.... get the word out!
Let's gooooo $SING
I am sorry for sounding foolish here, but why is there talk of a CUSPID # change?
-Michele
$BMSN
I have both, with more in ENTB as well....
Jriggity-
I only have 1,240,000 at an average price of $0.00078... If it goes bankrupt, I'm out $977....
Does anyone recall when we should expect the MIN application be submitted to the FDA?
I would think he meant $0.025 on approval from the FDA to start the trials... not the approval from the FDA for mass production...